Advances in Combined Immunotherapy for Triple Negative Breast Cancer
10.3971/j.issn.1000-8578.2022.22.0272
- VernacularTitle:三阴性乳腺癌的免疫联合治疗研究进展
- Author:
Hua WANG
1
;
Xiaolei HU
;
Xingyu LI
;
Ying DAI
Author Information
1. Department of Oncology, Ghe First Affiliated Hospital of Anhui Medical University, Hefei 230036, China
- Publication Type:Research Article
- Keywords:
Triple-negative breast cancer;
Checkpoint inhibitors;
ADC;
PARPi
- From:
Cancer Research on Prevention and Treatment
2022;49(10):996-1002
- CountryChina
- Language:Chinese
-
Abstract:
The triple-negative breast cancer has a relatively poor prognosis with limited therapeutic options. This subtype is highly immunogenetic and exhibits rich tumor infiltrated lymphocytes in the tumor microenvironment. However, immunotherapy alone is less effective as compared with the doublet of chemotherapy and immunotherapy in TNBC. The efficacy in early recurrence settings of mTNBC exceeds that in heavily treated subgroups. Meanwhile, other combinations including anti-angiogenesis, immune modulators, and PARPi elicit a promising effect. Herein, this paper reviews the progress of efficacy, safety, and the outlook in the immunotherapy of TNBC disease.
